Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from CANbridge Pharmaceuticals Inc. ( (HK:1228) ) is now available.
CANbridge Pharmaceuticals Inc. has announced that its board of directors will meet on March 28, 2025, to consider and approve the company’s annual results for the year ending December 31, 2024. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders and the company’s positioning within the pharmaceutical industry.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases and targeted cancers. The company operates with a market focus on providing advanced medical solutions to underserved patient populations.
YTD Price Performance: 21.54%
Average Trading Volume: 1,132,775
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$59.9M
For an in-depth examination of 1228 stock, go to TipRanks’ Stock Analysis page.